X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs FULFORD INDIA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE FULFORD INDIA CADILA HEALTHCARE/
FULFORD INDIA
 
P/E (TTM) x 32.6 398.8 8.2% View Chart
P/BV x 6.5 6.2 104.0% View Chart
Dividend Yield % 0.7 0.1 860.2%  

Financials

 CADILA HEALTHCARE   FULFORD INDIA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
FULFORD INDIA
Mar-14
CADILA HEALTHCARE/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs460942 48.8%   
Low Rs305450 67.8%   
Sales per share (Unadj.) Rs92.1691.4 13.3%  
Earnings per share (Unadj.) Rs14.811.5 129.3%  
Cash flow per share (Unadj.) Rs18.515.4 120.3%  
Dividends per share (Unadj.) Rs3.202.00 160.0%  
Dividend yield (eoy) %0.80.3 291.1%  
Book value per share (Unadj.) Rs68.0380.0 17.9%  
Shares outstanding (eoy) m1,023.743.90 26,249.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.21.0 412.5%   
Avg P/E ratio x25.860.7 42.5%  
P/CF ratio (eoy) x20.745.3 45.7%  
Price / Book Value ratio x5.61.8 307.2%  
Dividend payout %21.617.4 123.8%   
Avg Mkt Cap Rs m391,5812,714 14,426.0%   
No. of employees `00016.90.4 3,796.2%   
Total wages/salary Rs m15,002505 2,970.7%   
Avg. sales/employee Rs Th5,594.56,073.0 92.1%   
Avg. wages/employee Rs Th890.11,137.4 78.3%   
Avg. net profit/employee Rs Th899.9100.7 893.9%   
INCOME DATA
Net Sales Rs m94,2952,696 3,497.1%  
Other income Rs m1,286125 1,025.5%   
Total revenues Rs m95,5812,822 3,387.2%   
Gross profit Rs m19,036-46 -41,025.9%  
Depreciation Rs m3,75015 24,671.1%   
Interest Rs m45010 4,736.8%   
Profit before tax Rs m16,12254 29,690.6%   
Minority Interest Rs m3380-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,28910 13,427.1%   
Profit after tax Rs m15,16845 33,932.9%  
Gross profit margin %20.2-1.7 -1,173.1%  
Effective tax rate %8.017.7 45.2%   
Net profit margin %16.11.7 970.3%  
BALANCE SHEET DATA
Current assets Rs m60,2231,738 3,464.5%   
Current liabilities Rs m53,058545 9,740.8%   
Net working cap to sales %7.644.3 17.2%  
Current ratio x1.13.2 35.6%  
Inventory Days Days7048 144.1%  
Debtors Days Days884 2,048.0%  
Net fixed assets Rs m72,98412 613,310.9%   
Share capital Rs m1,02439 2,625.6%   
"Free" reserves Rs m68,5761,443 4,752.3%   
Net worth Rs m69,6001,482 4,696.4%   
Long term debt Rs m24,6840-   
Total assets Rs m152,2072,077 7,329.3%  
Interest coverage x36.86.7 548.4%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.61.3 47.7%   
Return on assets %10.32.6 393.2%  
Return on equity %21.83.0 722.5%  
Return on capital %17.94.3 416.5%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m21,28017 123,720.9%   
Fx outflow Rs m10,874673 1,615.4%   
Net fx Rs m10,406-656 -1,586.4%   
CASH FLOW
From Operations Rs m13,49590 14,994.4%  
From Investments Rs m-29,103105 -27,823.1%  
From Financial Activity Rs m23,158-14 -164,241.1%  
Net Cashflow Rs m7,556181 4,186.1%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 3.8 218.4%  
FIIs % 5.9 0.1 5,900.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 21.2 51.9%  
Shareholders   44,069 4,783 921.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALKEM LABORATORIES  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jan 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS